Asthma management review questions

1	In children, young people and adults with asthma who have not been treated previously, is it more clinically and cost effective to start treatment with a reliever alone (SABA) or with a reliever (SABA) and a preventer (such as ICS)?
2	What is the most clinically and cost effective first-line preventer drug (class or combination of drug classes) for the management of children, young people and adults with asthma who are uncontrolled on SABA alone (preventer-naïve or no preventer for at least 1 month)?
3	In people with a clinician diagnosis of asthma who are uncontrolled on low dose ICS, what is the most clinical and cost-effective second line preventer?
4	What is the most clinically and cost effective drug (class or combination of drug classes) for the management of children, young people and adults with asthma who are currently taking optimal preventer therapy beyond ICS low dose when this fails to provide adequate control?
5	In children, young people and adults with asthma on ICS preventer therapy or requiring ICS, is intermittent ICS more clinically and cost effective than regular ICS?
6	What are the clinical features (symptoms and/or objective measures) which indicate that a step down in treatment is appropriate?
7	What are the most clinically and cost-effective strategies to improve medicines adherence in children, young people and adults with asthma who are non-adherent to prescribed medicines?
8	What is the clinical and cost effectiveness of delivering asthma care stratified according to risk of asthma attacks to improve outcomes for children, young people and adults with asthma?
9	What is the clinical and cost effectiveness of supported self-management (including self-management education, self-monitoring and a personalised asthma action plan, PAAP) in comparison to standard care (asthma review only), for improving outcomes for children, young people and adults with asthma?
10	What is the optimal increase in ICS preventer therapy within supported self- management when control is lost?
11	Are breathing exercises clinically and cost effective for children, young people and adults with asthma?
12	What is the clinical and cost effectiveness of using ICS + LABA as preventer and reliever therapy compared to using ICS + LABA as preventer and a SABA as reliever therapy?